2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

SW1990 cells

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

2

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144661
    KRAS G12D inhibitor 14

    		Ras Apoptosis Cancer
    KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D .
    KRAS G12D inhibitor 14
  • HY-135770
    9-Dehydroxyeurotinone

    		Endogenous Metabolite Cancer
    9-Dehydroxyeurotinone is an anthraquinone derivative that can be found in Eurotium rubrum. 9-Dehydroxyeurotinone shows cytotoxicity with an IC50 value of 25 µg/mL for SW1990 cells .
    9-Dehydroxyeurotinone
  • HY-155303
    DCLK1-IN-2

    		Ser/Thr Protease Cancer
    DCLK1-IN-2 (compound I-5) is a potent DCLK1 inhibitor with an IC50 of 171.3  nM. DCLK1-IN-2 shows remarkable antiproliferative effects on SW1990 cell lines (IC50 of 0.6 μM) and in vivo antitumor potency .
    DCLK1-IN-2
  • HY-N12147
    Cannogenol 3-O-β-gentiobiosyl-(1→4)-α-L-thevetoside

    		Others Cancer
    Cannogenol 3-O-β-gentiobiosyl-(1→4)-α-L-thevetoside (Compound 12) is a cardiac glycoside that can be isolated from seeds of Thevetia peruvian. Cannogenol 3-O-β-gentiobiosyl-(1→4)-α-L-thevetoside shows cytotoxicity against SW1990 and MGC-803 cells (IC50: 9.52 and 7.70 μM) .
    Cannogenol 3-O-β-gentiobiosyl-(1→4)-α-L-thevetoside
  • HY-144338
    PARP1/BRD4-IN-1

    		Epigenetic Reader Domain PARP Apoptosis DNA/RNA Synthesis Cancer
    PARP1/BRD4-IN-1 is a potent and high selective PARP1/BRD4 inhibitor (IC50s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .
    PARP1/BRD4-IN-1
  • HY-182749
    KRAS-IN-58

    		Ras Akt Raf ERK Cancer
    KRAS-IN-58 is a KRAS inhibitor with a IC50 of 0.223 μM against KRAS G12D. KRAS-IN-58 binds to KRAS G12C and KRAS G12D proteins, and reduces the levels of phosphorylated Raf1, AKT and ERK in pancreatic cancer cells. KRAS-IN-58 can be used for the research of pancreatic cancer .
    KRAS-IN-58
  • HY-180200
    RNK08954

    		Ras ERK Cancer
    RNK08954 is an orally active KRASG12D inhibitor with a Kd of 0.0395 nM. RNK08954 selectively binds the inactive GDP-bound KRASG12D form, suppresses downstream KRAS-mediated signaling pathways p-ERK1/2 experssion. RNK08954 inhibits KRASG12D-mutant cell proliferation, induces G0-G1 cell cycle arrest, and inhibits tumor growth in mouse xenograft models. RNK08954 can be used for the research of non-small cell lung cancer, pancreatic ductal adenocarcinoma .
    RNK08954

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: